icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
AMaRC 19-02 - RECRUITMENT OPENED

Belantamab mafodotin (GSK2857916) is an investigational antibody-drug conjugate comprising a humanised anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent auristatin F via non-cleavable linker. BCMA is a pathway proven to be crucial for myeloma cell growth and survival; it is universally detected in myeloma cell lines. It is currently in clinical development by GlaxoSmithKline (GSK) together with Seattle Genetics in patients with relapsed/refractory multiple myeloma and other advanced haematologic malignancies expressing BCMA.

 

STATUS

Actively recruiting

Recruitment updated as of May 2021

 

TRIAL TITLE

A phase I/II single arm study of combination belantamab mafodotin, carfilzomib and dexamethasone in patients with early relapsed multiple myeloma.

 

STUDY DESIGN

Prospective, multicentre, open label trial, phase II study 

 

CORRELATIVE STUDIES

Blood and bone marrow samples will be collected as part of the trial to assess the immunological, epigenetics and molecular profile 

 

TRIAL PRINCIPAL INVESTIGATOR

Associate Professor Hang Quach

 

TIME FRAME

2020 – 2024

 

PARTICIPANTS

Patients with relapsed refractory multiple myeloma who have had 1 to 3 prior lines of treatment

 

CURRENT ENROLMENT

7 patients

 

STATUS

Recruiting

 

SITE LOCATIONS

Alfred Hospital, VIC

St Vincent's Hospital Melbourne, VIC